Compare Costco Wholesale Corporation (COST) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs GSK plc — how do they compare? Costco Wholesale Corporation trades at $925.79 (market cap $408.78B), while GSK plc trades at $51.59 (market cap $101.55B). The key difference: Costco Wholesale Corporation is far larger — about 4× GSK plc's market cap, and GSK plc pays the higher dividend (3.5%). Which is the better fit depends on your goals.
| COST | GSK | |
|---|---|---|
Market Cap | $408.78B | $101.55B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $61.18 |
52-Week Low | $849.63 | $36.20 |
Enterprise Value | $396.92B | $122.16B |
Dividend Yield | 0.64% | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco Wholesale Corporation (COST) trades at $923.76, down 0.29% on the day, as technical indicators signal a bearish trend with the price near pivot point support. Fundamentally, the company shows consistent revenue growth, reaching $275.24B in 2025, and strong cash flow generation of $13.34B from operations, though valuation metrics like a P/E of 46.37 appear elevated. Recent news highlights a March sales surge of 11.3% year-over-year and the first membership fee increase in seven years, which analysts view positively for future profit growth.
The investment outlook balances strong business fundamentals against a high valuation and near-term technical weakness. Upside potential is supported by robust membership renewal rates, expanding margins, and a consensus price target of $1,120. Key risks include sensitivity to consumer spending, competitive pressures in retail, and the stock's premium valuation requiring sustained execution to justify further gains.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
